In stable patients with coronary stenting receiving standard antiplatelet therapy , vorapaxar administered for long-term secondary prevention significantly reduced ARC definite ST , including very late ST. ( Trial to Assess the Effects of Vorapaxar -LSB- SCH @ ; MK-@ -RSB- in Preventing Heart Attack and Stroke in Patients With Atherosclerosis -LSB- TRA @ P-TIMI @ -RSB- -LSB- P@ -RSB- ; NCT@ ) .